In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new method called In Vivo Lung Perfusion (IVLP) to deliver chemotherapy directly into the lungs of patients with colorectal cancer that has spread to the lungs. The goal is to see if this technique can effectively kill tiny cancer cells in the lungs while reducing the harmful side effects typically associated with chemotherapy for other parts of the body. In this trial, participants will receive a chemotherapy drug called oxaliplatin in one lung during surgery, and doctors will closely monitor them for any side effects. As more people join the study, they may receive higher doses of the drug until the researchers find a dose that causes only temporary but severe side effects.

To be eligible for this trial, participants must be diagnosed with colorectal cancer that has spread to both lungs and have at least three lung lesions. They should be 70 years old or younger and generally healthy, with no serious heart or lung issues. Participants can expect to be carefully watched during the study, and the overall focus will be on ensuring their safety while finding the most effective dose of the treatment. This trial is currently looking for participants, and it’s important to note that those who have previously received certain treatments or are pregnant cannot join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of Colorectal Carcinoma
• • 2. Presence of bilateral pulmonary metastases
• • 3. 3 or more lung lesions in total
• • 4. Age 70 years or less
• • 5. ECOG 0-2
• • 6. Absence of extra-pulmonary disease, except liver metastases suitable to curative treatment.
• Exclusion Criteria:
• • 1. Patient has previously received more than 1000 mg of oxaliplatin
• • 2. Left Ventricular Ejection Fraction \<50%
• • 3. History of significant pulmonary disease or pneumonitis
• • 4. Pregnant or lactating females
• • 5. Age 71 or older, or less than 18 years
• • 6. Inability to understand the informed consent process
• • 7. Hypersenstivity to oxaliplatin
• • 8. Patients with Heparin-induced thrombocytopenia (HIT)
• • 9. Patients who cannot receive cefazolin or methylprednisolone due to allergy or another reason can be included but will not receive the drug they cannot tolerate
• • 10. Current participation in another therapeutic clinical trial